Definium Therapeutics Inc.
Organization details
- Legal name
- Definium Therapeutics Inc.
- Former names
- Mind Medicine (MindMed) Inc.
- Ownership
- Public
- Status
- Active
- Sector (GICS)
- Health Care
- SIC code
- 2833 — Medicinal Chemicals & Botanical Products
- Jurisdiction of incorporation
- British Columbia, Canada
- Headquarters city
- New York
- Headquarters state / province
- New York
- Headquarters country
- United States
- Fiscal year end
- December
- Ticker symbol
- DFTX
- Primary stock exchange
- Nasdaq
Identifiers
- SEC CIK
- 0001813814
- Wikidata ID
- Q107571756
Board of directors
-
Andreas Krebs · DirectorSince 2023
-
Carol A. Vallone · DirectorSince 2023
-
Daniel Karlin · Director · Chief Medical OfficerSince 2026
-
David W. Gryska · DirectorSince 2023
-
Miri Halperin Wernli · Director · Executive PresidentSince 2023
-
Robert Barrow · Director · Chief Executive OfficerSince 2023
-
Roger Adsett · DirectorSince 2026
-
Roger Crystal · DirectorSince 2023
-
Suzanne Louise Bruhn · DirectorSince 2023
Chief executives
Director election results
Annual meeting of June 11, 2026. Support is votes for as a share of votes for and against (or withheld). Below 80% is a clear protest.
-
95.2%
-
99.0%
-
99.1%
-
99.3%
-
99.5%
-
99.7%
-
99.8%
Board connections
2 of this board's directors also sit on 3 other boards. 3 are in the same sector.
-
Celcuity Inc. Same sectorvia David W. Gryska
-
Pliant Therapeutics Inc. Same sectorvia Suzanne Louise Bruhn
-
Travere Therapeutics Inc. Same sectorvia Suzanne Louise Bruhn
Insider trades
All notable trades →From SEC Forms 4 and 5. Open-market purchases and sales are highlighted; grants, option exercises and shares withheld for tax are routine.
- Bought, last 12 months
- $0
- 0 purchases by 0 insiders
- Sold, last 12 months
- $6,998,719
- 17 sales by 5 insiders
| Date | Insider | Transaction | Shares | Price | Value |
|---|---|---|---|---|---|
| Sep 25, 2026 | Robert Barrow Director, Officer (Chief Executive Officer) | Open-market sale | −31,550 | $36.57 | $1,153,784 |
| Sep 25, 2026 | Roberts Brandi Officer (Chief Financial Officer) | Open-market sale | −3,377 | $36.57 | $123,497 |
| Sep 25, 2026 | Sullivan Mark Officer (Chief Legal Officer) | Open-market sale | −14,051 | $36.57 | $513,845 |
| Sep 25, 2026 | Wiley Matthew T. Officer (Chief Commercial Officer) | Open-market sale | −3,097 | $36.57 | $113,257 |
| Sep 25, 2026 | Daniel Karlin Director, Officer (Chief Medical Officer) | Open-market sale | −10,853 | $36.57 | $396,894 |
| Sep 18, 2026 | Carol A. Vallone Director | Option exercise | +1,086 | $35.52 | $38,575 |
| Sep 18, 2026 | Andreas Krebs Director | Option exercise | +1,629 | $35.52 | $57,862 |
| Sep 14, 2026 | Robert Barrow Director, Officer (Chief Executive Officer) | Grant or award | +750,000 | — | — |
| Sep 14, 2026 | Roberts Brandi Officer (Chief Financial Officer) | Grant or award | +125,000 | — | — |
| Sep 14, 2026 | Sullivan Mark Officer (Chief Legal Officer) | Grant or award | +125,000 | — | — |
| Sep 14, 2026 | Wiley Matthew T. Officer (Chief Commercial Officer) | Grant or award | +125,000 | — | — |
| Sep 14, 2026 | Daniel Karlin Officer (Chief Medical Officer) | Grant or award | +200,000 | — | — |
| Sep 3, 2026 | Robert Barrow Director, Officer (Chief Executive Officer) | Open-market sale | −19,023 | $37.94 | $721,733 |
| Sep 2, 2026 | Robert Barrow Director, Officer (Chief Executive Officer) | Grant or award | +40,000 | — | — |
| Aug 12, 2026 | Robert Barrow Director, Officer (Chief Executive Officer) | Grant or award | +375,000 | — | — |
Peers
Compare boardsOrganizations in the same sector, closest in location and size first.
Questions about Definium Therapeutics Inc.
Who is the CEO of Definium Therapeutics Inc.?
Robert Barrow is Definium Therapeutics Inc.'s Chief Executive Officer.
How many directors are on Definium Therapeutics Inc.'s board?
Definium Therapeutics Inc.'s board has 9 directors: Andreas Krebs, Carol A. Vallone, Daniel Karlin, David W. Gryska, Miri Halperin Wernli, Robert Barrow, Roger Adsett, Roger Crystal and Suzanne Louise Bruhn.
Are Definium Therapeutics Inc. insiders buying or selling shares?
Over the last 12 months, Definium Therapeutics Inc. insiders made no open-market purchases and sold $7.0 million of shares in 17 sales on the open market, as reported to the SEC on Forms 4 and 5.
Embed this board on your site
Paste this where the board should appear. It always shows the current directors and links back here.
<div data-bod-board="definium-therapeutics-inc"></div>
<script src="https://boardofdirectors.review/embed.js" async></script>Reviews (0)
Sign in to write a review.
No reviews yet. Be the first to write one.